Table 2.
Clinical characteristics of patients and controls.
| Controls (n = 30) | HF− (n = 30) | HF+ (n = 29) | |
|---|---|---|---|
| Age (years) * | 70 (60–77) | 70 (63–76) | 72 (60–77) |
| Male sex † | 21 (70%) | 22 (73%) | 18 (62%) |
| European ethnicity † | 26 (87%) | 25 (83%) | 21 (72%) |
| Cigarette smoker † | 0 (0%) | 0 (0%) | 1 (3%) |
| SBP (mmHg) * | 140 (130–149) | 135 (121–160) | 130 (111–143) |
| BMI (kg/m2) * | 29 (25–33) | 29 (26–33) | 29 (25–34) |
| Diagnosis † | - | UA: 7 (23%) | UA: 6 (21%) |
| - | NSTEMI: 15 (50%) | NSTEMI: 16 (55%) | |
| - | STEMI: 8 (27%) | STEMI: 7 (24%) | |
| Type 2 Diabetes † | 2 (7%) | 11 (37%) | 11 (38%) |
| Hypertension † | 9 (30%) | 22 (73%) | 22 (76%) |
| Atrial fibrillation † | 0 (0%) | 5 (17%) | 5 (17%) |
| Creatinine (μg/L) * | 92 (78–99) | 97 (85–109) | 102 (99–116) |
| hsTnI (ng/L) * | 2.9 (1.7–5.1) | 8.0 (5.8–14.9) | 11.1 (6.7–24.3) |
| NT-proBNP (pmol/L) * | 8.0 (3.8–25.3) | 92 (47–141) | 146 (67–233) |
| LVEF (%) * | 68 (63–74) | 64 (52–75) | 64 (52–75) |
| Beta blockers † | 3 (10%) | 27 (90%) | 23 (79%) |
| ACE inhibitors or ARBs † | 5 (17%) | 19 (63%) | 18 (62%) |
| Statins † | 8 (27%) | 27 (90%) | 27 (93%) |
| Diuretics † | 3 (10%) | 8 (27%) | 10 (35%) |
* Median (interquartile range); † number of patients (%); ACE, angiotensin-converting enzyme; ARB, angiotensin II type I receptor blockers; BMI, body mass index; eGFR, estimated glomerular filtration rate; hsTnI, high sensitivity troponin I; NSTEMI, non ST-elevation myocardial infarction; NT-proBNP, amino-terminal pro B-type natriuretic peptide; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; UA, unstable angina.